| COVID-19 and healthcare impacts | Lifetime | 5 | IT 1 | 99.84 |
| Advanced Breast Cancer Therapies | Lifetime | 12 | IT 1 | 99.83 |
| Cancer Treatment and Pharmacology | Lifetime | 35 | IT 1 | 99.84 |
| HER2/EGFR in Cancer Research | Lifetime | 23 | IT 2 | 99.82 |
| Breast Cancer Treatment Studies | Lifetime | 36 | IT 4 | 99.84 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 69 | IT 3 | 99.80 |
| Cancer Genomics and Diagnostics | Lifetime | 141 | IT 3 | 99.67 |
| Economic and Financial Impacts of Cancer | Lifetime | 30 | IT 1 | 99.33 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 209 | IT 4 | 99.57 |
| Lung Cancer Treatments and Mutations | Lifetime | 226 | IT 12 | 99.40 |
| CAR-T cell therapy research | Lifetime | 184 | IT 9 | 99.34 |
| Cancer Cells and Metastasis | Lifetime | 173 | IT 7 | 99.08 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 36 | IT 2 | 98.85 |
| COVID-19 Clinical Research Studies | Lifetime | 302 | IT 34 | 98.69 |
| Immunotherapy and Immune Responses | Lifetime | 639 | IT 18 | 98.98 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 458 | IT 32 | 98.73 |
| PARP inhibition in cancer therapy | Lifetime | 142 | IT 9 | 97.91 |
| Cancer-related Molecular Pathways | Lifetime | 520 | IT 16 | 98.19 |
| Colorectal Cancer Treatments and Studies | Lifetime | 578 | IT 50 | 98.34 |
| Lung Cancer Research Studies | Lifetime | 537 | IT 37 | 98.09 |
| BRCA gene mutations in cancer | Lifetime | 445 | IT 12 | 97.05 |
| Biosimilars and Bioanalytical Methods | Lifetime | 203 | IT 11 | 96.35 |
| Genetic factors in colorectal cancer | Lifetime | 846 | IT 45 | 97.32 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 380 | IT 13 | 97.05 |
| Breast Lesions and Carcinomas | Lifetime | 500 | IT 27 | 96.73 |
| Global Cancer Incidence and Screening | Lifetime | 905 | IT 27 | 96.36 |
| Brain Metastases and Treatment | Lifetime | 876 | IT 36 | 95.01 |
| Advances in Oncology and Radiotherapy | Lifetime | 488 | IT 15 | 92.08 |
| Male Breast Health Studies | Lifetime | 100 | IT 10 | 88.05 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 1 | IT 1 | 99.98 |
| Cancer Genomics and Diagnostics | 2021-2025 | 3 | IT 1 | 99.96 |
| HER2/EGFR in Cancer Research | 2021-2025 | 1 | IT 1 | 99.98 |
| Breast Cancer Treatment Studies | 2021-2025 | 2 | IT 1 | 99.98 |
| Cancer Treatment and Pharmacology | 2021-2025 | 2 | IT 1 | 99.98 |
| Advanced Breast Cancer Therapies | 2021-2025 | 4 | IT 1 | 99.95 |
| Cancer Cells and Metastasis | 2021-2025 | 7 | IT 1 | 99.06 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 30 | IT 4 | 99.87 |
| CAR-T cell therapy research | 2021-2025 | 51 | IT 4 | 99.62 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 57 | IT 4 | 99.62 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 6 | IT 1 | 98.50 |
| Genetic factors in colorectal cancer | 2021-2025 | 44 | IT 8 | 98.47 |
| Immunotherapy and Immune Responses | 2021-2025 | 86 | IT 2 | 98.43 |
| BRCA gene mutations in cancer | 2021-2025 | 31 | IT 5 | 98.43 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 53 | IT 7 | 99.12 |
| COVID-19 and healthcare impacts | 2021-2025 | 102 | IT 12 | 97.49 |
| Lung Cancer Research Studies | 2021-2025 | 63 | IT 4 | 99.00 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 35 | IT 2 | 98.22 |
| Global Cancer Incidence and Screening | 2021-2025 | 65 | IT 4 | 98.17 |
| Estrogen and related hormone effects | 2021-2025 | 24 | IT 2 | 97.12 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 116 | IT 6 | 98.54 |
| Cancer-related Molecular Pathways | 2021-2025 | 38 | IT 2 | 96.74 |
| Brain Metastases and Treatment | 2021-2025 | 60 | IT 6 | 97.19 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 365 | IT 16 | 96.52 |
| Radiomics and Machine Learning in Medical Imaging | 2021-2025 | 672 | IT 65 | 95.81 |
| Peptidase Inhibition and Analysis | 2021-2025 | 235 | IT 14 | 95.00 |
| PARP inhibition in cancer therapy | 2021-2025 | 141 | IT 9 | 95.06 |
| Breast Lesions and Carcinomas | 2021-2025 | 98 | IT 13 | 95.05 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 266 | IT 54 | 94.34 |
| Advances in Oncology and Radiotherapy | 2021-2025 | 186 | IT 9 | 88.28 |
| Cancer Diagnosis and Treatment | 2021-2025 | 373 | IT 30 | 84.35 |
| Chemotherapy-induced cardiotoxicity and mitigation | 2021-2025 | 313 | IT 26 | 83.46 |
| Radiopharmaceutical Chemistry and Applications | 2021-2025 | 865 | IT 44 | 86.38 |
| DNA Repair Mechanisms | 2021-2025 | 683 | IT 13 | 82.34 |
| Cancer Research and Treatments | 2021-2025 | 923 | IT 16 | 78.71 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 747 | IT 34 | 75.77 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 713 | IT 52 | 71.72 |
| Galectins and Cancer Biology | 2021-2025 | 683 | IT 23 | 69.92 |
| Cancer, Stress, Anesthesia, and Immune Response | 2021-2025 | 492 | IT 9 | 69.10 |
| Science, Research, and Medicine | 2021-2025 | 126 | IT 1 | 55.62 |
| Male Breast Health Studies | 2021-2025 | 183 | IT 23 | 45.39 |
| TGF-β signaling in diseases | 2021-2025 | 507 | IT 16 | 35.24 |
